Effects of terguride, a partial D2 agonist, on MPTP‐lesioned parkinsonian cynomolgus monkeys
- 1 May 1993
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 33 (5), 507-511
- https://doi.org/10.1002/ana.410330515
Abstract
Behavioral effects of terguride, a partial dopamine D2 agonist, on 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–lesioned parkinsonian cynomolgus monkeys were compared with those of the dopamine agonist apomorphine and the dopamine antagonist haloperidol. Terguride alone ameliorated the parkinsonism without inducing any sign of excitability, irritability, or aggressiveness (hyperactivity). Apomorphine alone also ameliorated the parkinsonism but induced marked hyperactivity. Haloperidol alone caused worsening of the parkinsonism, inducing transient eyelid closure. In combination with apomorphine, terguride suppressed the hyperactivity induced by apomorphine without reducing its antiparkinsonian effets. Pretreatment with haloperidol suppressed both the antiparkinsonian effects and the hyperactivity induced by apomorphine. Terguride thus exhibits both antiparkinsonian and antihyperactivity effects in a monkey model of Parkinson's disease, suggesting that terguride might be beneficial for treating motor dysfunction and dopaminergic psychosis in advanced Parkinson's disease.Keywords
This publication has 18 references indexed in Scilit:
- Lisuride, a dopamine agonist in the treatment of early Parkinson's diseaseNeurology, 1989
- Reappraisal of Temporary Levodopa Withdrawal (Drug Holiday) in Parkinson's DiseaseNew England Journal of Medicine, 1985
- Combined bromocriptine‐levodopa therapy early in Parkinson's diseaseNeurology, 1985
- Dual action on central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisurideLife Sciences, 1983
- A DANGER IN MAKING THE DIAGNOSIS OF PARKINSON'S DISEASEThe Lancet, 1982
- Treatment of advanced Parkinson disease with pergolideNeurology, 1981
- Study of deterioration in long-term treatment of parkinsonism with L-Dopa plus decarboxylase inhibitorJournal of Neural Transmission, 1976
- "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPYThe Lancet, 1976
- The mechanisms of action of L-dopa in Parkinson's diseaseLife Sciences, 1974
- Psychiatric Side Effects of Levodopa in ManPublished by American Medical Association (AMA) ,1971